Exercise for Tumor Suppressive Impact in Men With Prostate Cancer at High-Risk of Progression on Active Surveillance: The REMOVE Trial

July 13, 2026 updated by: Fred Hutchinson Cancer Center

The purpose of this study is to determine whether a 12-week, home-based, virtually supervised exercise program will slow cancer progression of prostate cancer among men with prostate cancer at high-risk of progression undergoing active surveillance.

The name of the study intervention involved in this study is:

Aerobic high-intensity interval training (HIIT) (training exercise intervention)

Study Overview

Detailed Description

This research study is a randomized controlled study for a home-based, virtually supervised, aerobic exercise intervention for men with prostate cancer at high-risk of progression undergoing active surveillance. There is evidence that exercise may suppress cancer progression, but the evidence is preliminary.

Participants will be randomized into one of two treatment groups: Group A: Aerobic high-intensity interval training (HIIT) versus Group B: Waitlist Control. Randomization means a participant is placed into a study group by chance.

The research study procedures include screening for eligibility, study treatment visits, survey questionnaires, blood tests, and follow-up visits.

Participation in this research study is expected to last about 14 weeks.

It is expected that about 68 people will take part in this research study.

The Prostate Cancer Foundation is providing funding for this research study.

Study Type

Interventional

Enrollment (Estimated)

68

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Massachusetts
      • Boston, Massachusetts, United States, 02215
        • Completed
        • Beth Israel Deaconess Medical Center
      • Boston, Massachusetts, United States, 02215
        • Completed
        • Dana-Farber Cancer Institute
      • Boston, Massachusetts, United States, 02215
        • Completed
        • Brigham and Women's Hospital
    • Washington
      • Seattle, Washington, United States, 98109
        • Recruiting
        • Fred Hutch/University of Washington Cancer Consortium
        • Principal Investigator:
          • Dong-Woo Kang, PhD
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Age ≥18 years.
  • Histologically diagnosed with localized prostate cancer.
  • Initiating or undergoing active surveillance.
  • Having a higher risk of progression, defined as meeting one or more of the following: (1) favorable- intermediate risk prostate tumor at diagnosis, (2) obesity (body mass index ≥ 30), and/or (3) self- identified as Black or African American.
  • No plans for invasive treatment for their prostate cancer in the 12 weeks following the time of enrollment.
  • Ability to understand and willingness to provide informed consent.

Exclusion Criteria:

  • Received any invasive curative-intent treatment for prostate cancer, including surgery, chemotherapy, radiation therapy, and hormonal therapy.
  • Patients with metastasis and/or other active malignancies (except basal cell carcinoma) and/or receiving treatment for those malignancies.
  • Participating in any (>0 min/week) high-intensity exercise at the time of recruitment.
  • Having chronic medical conditions that are clinically unstable or uncontrolled with medications, deemed high-risk for exercise. These include but are not limited to unstable cardiac diseases, uncontrolled diabetes, and bone metastases with imminent risk of fracture.
  • Having a high risk for noncompliance with study procedures. This will be determined by the study team based on the history of missed oncology appointments (i.e., ≥3 no-shows in 6 months) and poor responsiveness during recruitment (i.e., ≥3 unreturned contacts).
  • Patients who are non-English speaking and unable to complete the participant surveys.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Group A: HIIT Exercise Program

Participants will be allocated in a 1:1 ratio, using a permuted blocked design with varying block size. Study procedures will be conducted as follows:

  • Testing visits at Week 1 and 14 for physical exams, physical fitness and function assessments, survey questionnaires, and cardiopulmonary fitness assessment.
  • Virtual, aerobic training sessions three times weekly with trained oncology exercise specialist.
Home-based, virtually supervised, aerobic exercise program of 36 sessions accessible via internet-enabled tablet (provided to participant if needed). Participants will be supplied with stationary bike, heart rate monitor, and blood pressure monitor.
(Optionally) Home-based, virtually supervised, aerobic exercise program of 36 sessions accessible via internet-enabled tablet (provided to participant if needed). Participants will be supplied with stationary bike, heart rate monitor, and blood pressure monitor.
Experimental: Group B: Waitlist Control

Participants will be allocated in a 1:1 ratio, using a permuted blocked design with varying block size. Study procedures will be conducted as follows:

  • Testing visits at Week 1 and 14 for physical exams, physical fitness and function assessments, and survey questionnaires.
  • Upon completion of post-intervention assessments, participants will have the option to take part in the 12-week HIIT exercise program.
Home-based, virtually supervised, aerobic exercise program of 36 sessions accessible via internet-enabled tablet (provided to participant if needed). Participants will be supplied with stationary bike, heart rate monitor, and blood pressure monitor.
(Optionally) Home-based, virtually supervised, aerobic exercise program of 36 sessions accessible via internet-enabled tablet (provided to participant if needed). Participants will be supplied with stationary bike, heart rate monitor, and blood pressure monitor.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Prostate-Specific Antigen (PSA) Level
Time Frame: Baseline (Week 1) and post-intervention (Week 14)
The primary outcome is the between-group difference in prostate-specific antigen (PSA) levels post-intervention. Analysis of covariance will be used to detect the difference adjusting for baseline values of the outcome and other covariates.
Baseline (Week 1) and post-intervention (Week 14)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Prostate-Specific Antigen (PSA) Velocity
Time Frame: Baseline (Week 1) and post-intervention (Week 14)
PSA velocity will be calculated following the PSA Working Group Guidelines, using the three most recent PSA values obtained from the medical chart with the first and last values being at least three months apart. The formula was based on the natural logarithm of 2 (0.693) divided by the slope obtained from fitting a linear regression of the natural log of PSA.
Baseline (Week 1) and post-intervention (Week 14)
Prostate-Specific Antigen (PSA) Doubling Time
Time Frame: Baseline (Week 1) and post-intervention (Week 14)
PSA doubling time will be calculated following the PSA Working Group Guidelines, using the three most recent PSA values obtained from the medical chart with the first and last values being at least three months apart. PSA velocity will be used to calculate the number of years that PSA levels become doubles, where the longer the time the better the prognosis.
Baseline (Week 1) and post-intervention (Week 14)
Proliferation of LNCaP Prostate Cancer Cell Line
Time Frame: Baseline (Week 1) and post-intervention (Week 14)
LNCaP cells are androgen-sensitive human prostate adenocarcinoma cells. LNCaP cells will be grown in vitro and their growth rate will be measured by counting the number of cells over time.
Baseline (Week 1) and post-intervention (Week 14)
Muscular Strength
Time Frame: Baseline (Week 1) and post-intervention (Week 14)
Muscular strength will be measured as 1-repetition maximum (RM) (i.e., the greatest resistance that can be moved through the full range of motion), which has been the standard for strength assessments. 1-RM values will be estimated from 10-RM using validated equations on 2 exercises (chest press and leg press).
Baseline (Week 1) and post-intervention (Week 14)
Short Physical Performance Battery (SPPB)
Time Frame: Baseline (Week 1) and post-intervention (Week 14)
Physical function will be assessed by the Short Physical Performance Battery (SPPB), which includes the following 3 lower extremity measures completed in the following order. Timed balance (seconds): Balance will be assessed under 3 conditions (side-by-side, semi-tandem, and tandem stands). Gait speed (seconds): Gait speed will be assessed over a 4-meter flat surface distance. The participant will be asked to complete 2 attempts of this test. Time will be recorded using an electronic timing system. Chair stand (seconds): Chair stand will be performed under 2 conditions: a) subjects will perform a single chair stand; b) subjects will be asked to perform 5 repeated chair stands as quickly as possible; time to completion will be recorded.
Baseline (Week 1) and post-intervention (Week 14)
Health-Related Quality of Life
Time Frame: Baseline (Week 1) and post-intervention (Week 14)
The European Organization for Research and Treatment of Cancer- Quality of Life Questionnaire-C30 (EORTC-QLQ C30) will assess health-related quality of life, consisting of subscales including functional scales (physical, role, cognitive, emotional, social), symptom scales (fatigue, pain, and nausea and vomiting), global health status and quality of life scale, also several single-item symptom measures. The score ranges from 0 to 100 and a higher value indicates a better quality of life.
Baseline (Week 1) and post-intervention (Week 14)
Prostate Cancer-Specific Anxiety
Time Frame: Baseline (Week 1) and post-intervention (Week 14)
Assessed by the Memorial Anxiety Scale for Prostate Cancer (MAX-PC), an 18-item questionnaire with a 4-point Likert-type scale asking how frequently certain "comments made by men about prostate cancer" were true of the respondent. Each item is scored from 0 to 4 with anchors ranging from "Not at all" to "Often."
Baseline (Week 1) and post-intervention (Week 14)
Fear of Cancer Progression Assessment
Time Frame: Baseline (Week 1) and post-intervention (Week 14)
The Fear of Cancer Recurrence Inventory (FCRI) is a well-established scale for in-depth assessment of FCR in research. The short form of this measure (FCRI-SF), consisting of 9 items, has been used as a tool to screen for clinical levels of fear of cancer recurrence (FCR). The FCRI-SF is often used to identify potential cases of clinically significant FCR.
Baseline (Week 1) and post-intervention (Week 14)
Cardiorespiratory Fitness
Time Frame: Baseline (Week 1) and post-intervention (Week 14)
Cardiorespiratory fitness will be assessed as VO2peak by a graded maximal or submaximal cycle exercise stress test. VO2peak is defined as the highest values of oxygen uptake averaged among every 30-second interval during the test. VO2peak will be reported in both relative (ml·kg-1·min-1) and absolute (L/min) terms.
Baseline (Week 1) and post-intervention (Week 14)
Sleep Quality
Time Frame: Baseline (Week 1) and post-intervention (Week 14)
Sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI). The PSQI is a self-rated questionnaire which assesses sleep quality and disturbances over a 1-month. The PSQI contains 19 self-rated questions and 5 questions rated by the bed partner or roommate (if one is available). Only self-rated questions are included in the scoring. The self-rated items are combined to form seven "component" scores, each of which has a range of 0-3 points, and they are summed to obtain a global score ranging from 0-21 points, where a higher score indicates worse sleep quality.
Baseline (Week 1) and post-intervention (Week 14)
Body Composition
Time Frame: Baseline (Week 1) and post-intervention (Week 14)
Body composition will be assessed using Bioelectrical Impedance Analysis (BIA). Participants will stand on the device while holding the handles with their arms at their sides, and the device will estimate percent body fat using an algorithm based on age, sex, height, and body weight. Supporting anthropometric measures will include height (stadiometer), body weight (calibrated digital scale), and waist and hip circumference (constant-tension tape measure). Body fat will be reported as a percentage (%), with body weight reported in kilograms (kg).
Baseline (Week 1) and post-intervention (Week 14)
Prostate Cancer Symptoms
Time Frame: Baseline (Week 1) and post-intervention (Week 14)
Prostate cancer-specific symptoms will be assessed using the Expanded Prostate Cancer Index Composite-26 (EPIC-26), a 26-item questionnaire evaluating five domains: urinary incontinence, urinary irritative/obstructive, bowel, sexual, and hormonal function. Each domain is scored from 0 to 100, where a higher score indicates better function and fewer symptoms.
Baseline (Week 1) and post-intervention (Week 14)
Exercise Benefits and Barriers
Time Frame: Baseline (Week 1) and post-intervention (Week 14)
Perceptions of the benefits of and barriers to exercise will be assessed using a study-specific Exercise Benefits/Barriers questionnaire with two parts: perceived benefits/harms of the program (7 items rated -3 [very much worse] to +3 [very much better], higher = greater benefit) and perceived barriers to completing the program (14 items rated 1 [not at all] to 7 [very much], higher = greater barriers).
Baseline (Week 1) and post-intervention (Week 14)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Dong-Woo Kang, PhD, Fred Hutch/University of Washington Cancer Consortium

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2024

Primary Completion (Estimated)

March 31, 2027

Study Completion (Estimated)

March 31, 2027

Study Registration Dates

First Submitted

June 14, 2023

First Submitted That Met QC Criteria

June 23, 2023

First Posted (Actual)

June 26, 2023

Study Record Updates

Last Update Posted (Actual)

July 15, 2026

Last Update Submitted That Met QC Criteria

July 13, 2026

Last Verified

July 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • RG1125288
  • 20857 (Other Identifier: Fred Hutch/University of Washington Cancer Consortium)
  • NCI-2023-07008 (Registry Identifier: CTRP (Clinical Trial Reporting Program))

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on ClinicalTrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

IPD Sharing Time Frame

Data can be shared no earlier than 1 year following the date of publication

IPD Sharing Access Criteria

Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe